Holding the 'miracle drug for weight loss', Novo Nordisk generates 133.4 billion DKK in revenue in H1 2024
youki676
发表于 2024-8-8 11:16:41
1250
0
0
On August 7, 2024, Novo Nordisk released its financial report for the first half of 2024, with operating revenue of 133.4 billion Danish kroner (DKK), equivalent to 19.5 billion US dollars, a year-on-year increase of 24%; Net profit was 45.5 billion Danish kroner, equivalent to 6.65 billion US dollars, a year-on-year increase of 16%. Among them, the sales revenue of semaglutide is nearly 13 billion US dollars, just one step away from the throne of the drug king.
In addition, Novo Nordisk has revealed that its Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. From the perspective of the domestic market, there are currently four GLP-1 receptor agonists approved for weight loss indications, and multiple GLP-1 RA products are in the stage of market application or clinical phase III for weight loss indications, with a focus on the relevant developments in biotechnology and other concepts.
Related ETFs: Biotechnology ETF (516500), Hang Seng Pharmaceutical ETF (159892)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- "다이어트의 신약"을 손에 쥐고 노허노드 2024H1 1334억 DKK 수익 창출
- Oral "weight loss medication" further advances Novo Nordisk oral semaglutide weight loss phase III research success
- Is the dual monopoly situation of Novo Nordisk Lilly in danger? By 2029, there may be 16 GLP-1 weight loss drugs on the market
- Too sudden! TeBai Hui applies for bankruptcy protection, netizen: once every person had one
- Novo Nordisk faces US Senate inquiry over weight loss drug prices
- The US Senate questions whether the pricing of the "weight loss miracle drug" is too high. Nuo and Nuo De respond that lowering the price is useless
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
-
随着“银十”结束,各家造车新势力都交出了一份亮眼的成绩单。 理想领跑10月新势力交付榜,鸿蒙智行重回4万辆,零跑、深蓝、极氪、小鹏等单月交付量均创新高,岚图、阿维塔、智己等实现破万,但哪吒却消失在 ...
- fanadam
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
为期超七周的大罢工终于落下帷幕。 当地时间11月4日,波音美国西海岸工厂工人们就改进后的合同提案投票。 随后,代表着波音超过33000名西雅图地区机械师的IAM工会经表决,以59%的同意票决定接纳波音提 ...
- cristianna
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
“新四化”的时代浪潮下,新能源汽车行业百家争鸣。伴随着自主品牌不断崛起,合资品牌当下的生存状况备受外界关注,如何打好电动化时代的突围战,成为合资品牌的新课题。 作为国内合资车企的代表之一,上汽 ...
- mbgg2797
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
证券时报网讯,热门中概股美股盘前普涨,小鹏汽车、哔哩哔哩涨近5%,蔚来涨超4%,阿里巴巴、拼多多涨超2%。
- p609520
- 3 天前
- 支持
- 反对
- 回复
- 收藏